← The Wire·Breaking·Earnings·

NervGen to restate 2025 and June 2026 financial statements

NervGen will restate its 2025 annual and June 2026 interim financial statements for non-cash accounting adjustments. The filing change introduces reporting uncertainty for a late-stage biotech whose valuation depends heavily on clinical and financing milestones.

The story

NervGen said on Sept. 25 that it will restate its audited financial statements for the year ended Dec. 31, 2025, and its unaudited interim statements for the quarter ended June 30, 2026. The company described the changes as non-cash accounting adjustments.

The restatement reaches both the most recent annual accounts and the latest interim reporting, rather than a single historical period. No further details on the adjustments or their effect on the statements are established here.

NervGen is developing neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. The accounting change therefore sits alongside a late-stage clinical program, where future value is tied to development progress and the ability to fund operations.

The size and direction of the revisions, the accounting items involved and the timing of amended filings remain open questions. Investors will need the restated statements and the company's explanation of the adjustments to determine whether the change affects reported assets, liabilities, expenses or other measures.

Our read · Fri, Sep 25

NervGen (NGEN) will restate 2025 annual and June 2026 interim financial statements for non-cash accounting adjustments.

Why. The immediate consequence is reporting uncertainty rather than a stated cash impact, and the absence of detail on the adjustments prevents a defensible directional equity call. The restated annual and interim accounts will determine whether the issue is confined to presentation or changes the financial picture supporting NervGen's late-stage development program.

Both cases

The case it holdsThe company describes the adjustments as non-cash, so the restatement may leave liquidity and the clinical program's operating path unchanged.
The case it breaksThe restatement covers both the 2025 annual accounts and June 2026 interim statements, leaving the scope and effect of the accounting changes unresolved until amended filings appear.

What could change this view: The read is invalidated if the restated statements show only immaterial presentation changes with no effect on key financial measures.

Ngen stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Keep reading

Latest on the Wire

Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by GlobeNewswire as NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →